Trump Reclassifies State-Licensed Medical Marijuana as a Less-Dangerous Drug in a Historic Shift

The federal reclassification of state-licensed medical marijuana from Schedule I to Schedule III marks a significant regulatory shift with direct public health implications. The order, signed April 24, 2026, legitimizes medical cannabis programs in 40 states, removes research penalties for scientists using state-licensed cannabis, and opens a pathway for expanded clinical study of safety and efficacy.

 

Critics note that the reclassification sends an ambiguous public message about cannabis-related harms at a time when product potency in legalized markets warrants closer scrutiny. Non-medical marijuana and products outside state-licensed systems retain Schedule I status.

A broader reclassification hearing is scheduled to begin in late June 2026. Learn more from AP here.